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Abstract--In this paper we use a data set for which a relevant control group is unavailable to evaluate 
benefits of X-ray screening for lung cancer. Bias-free analyses are difficult with such data. We compare 
survivals of screen-detected and clinically diagnosed cases, adjusting for screening biases as part of the 
survival analysis. Our results, without a control group, are that significant bias-free survival benefits exist 
for screen-detected cases as compared with those clinically diagnosed. The significant mortality reduction 
indicated here, even without a control group, suggests that the debate on X-ray screening for early 
detection of lung cancer of high risk, apparently healthy, individuals is not over yet. 
1. INTRODUCTION 
The need and the advantage of having a randomized control group in assessing the benefits of 
screening in terms of survival differences between screen and clinically-detected cancer patients, 
cannot be over-emphasized. In the analysis of breast cancer screening data from the HIP study [1], 
it was shown that without a control group, only a very "modest" mortality reduction due to 
screening could be concluded. A much larger estimate of the reduction isobtained when the control 
group is included in the analysis. 
One of the most reliable methods, currently available, to evaluate benefits of periodic screening, 
is a comparison of total mortality in the entire screened population with that in a randomly selected 
control population. This seems to be the only method which completely safeguards against he 
practical and theoretical difficulties encountered in interpreting and evaluating results of screening. 
The foremost stumbling block in nonrandomized studies, being, what is commonly known as 
screening biases. Major screening biases are lead time, length sampling, over-diagnosis and 
self-selection (for definitions, see Habbema et al. [1]). 
Not withstanding the merits of a randomized esign, there could exist scenarios with some 
screening procedures (e.g. chest X-ray for early lung cancer detection) which are already embedded 
in general medical practice and are routinely carried out. It may be unethical and impractical to 
carry out a randomized study that would necessitate withholding the screening method for some 
of the participants. Consequently, there could exist a wealth of enormous data where a screening 
procedure could have been periodically used, bnt a relevant randomized "control" group (without 
screen) is unavailable. 
One such data set resulted uring a large scale multicenter lung cancer screening study primarily 
designed to study the effectiveness of the periodic screening by sputum cytology in early detection 
of lung cancer. The ELC study (early lung cancer detection) design included X-ray screened group 
but a control group (NO X-ray screen) was not included. Consequently, evaluation of periodic 
X-ray, as an effective screening tool for early detection of lung cancer cannot be done on the basis 
of randomized control group co/nparisons. 
In the present paper, we attempt to assess benefits from X-ray screening for early lung cancer 
detection. We analyze the X-ray screening data obtained from the cooperative early lung cancer 
(ELC) study [2]. We recognize that without having a randomized control group, such evidence 
of benefits of screening, is at best a "softer" evidence. Nevertheless, such an alternative approach of 
analysing an existing data is a worthwhile attempt at extracting some estimates of the benefits of 
chest X-ray screening for lung cancer detection--a question which still has some controversy. 
The purpose of this paper is to assess if benefits exist in the post diagnosis urvival of the 
patients found by periodic screening. In achieving this aim we develop a simplified model for 
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the effect of periodic screening for lung cancer by estimating certain parameters of screening biases 
such as lead time and/or length sampling and then adjusting those biases as part of the survival 
analyses. In the absence of a control group (no screen group), these biases can only be indirectly 
estimated. 
We assume that the disease progresses in the manner shown below: 
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Schema for the progression of a chronic disease, with the intervention of an early detection 
screening test (cf. Day and Walter [3]). 
An individual enters the preclinical phase of the disease, detectable by the screening modality 
in question, at time To, and would begin to manifest symptoms, at time T~, if no intervention 
were to take place. For this individual, the "sojourn time" is defined as T I -  To. Suppose 
now that the individual is screened at time T: (To < T2 < Tl) and the principal state diagnosed. 
For this individual, the "lead time" is defined as T t -T  2. The probability that the screening test 
correctly identifies an individual as being in the preclinical state is termed the "sensitivity" of 
the test. 
A review of the role that one might expect models to play in the evaluation of screening 
programmes and of screening strategies i  given by the working group set up to review the breast 
cancer detection and demonstration projects in the United States [4]. General models have been 
developed [5-9] to describe the effect of screening on the disease process in order to identify those 
parameters which determine the expected benefit. Estimation of parameters of interest is difficult 
with these general models since the number of unknowns is large. 
Assumptions for the estimation of lead time distribution 
In the present paper, we have followed the approach of Day and Walter [3]. In a mass screening 
program one usually has at least the following data: 
(i) The prevalence of the diagnosed preclinical state at different screens, together 
with the interval between the screens. 
(ii) The incidence of the clinical disease both before screening, and after screening 
among individuals creened negative at one or more screens. 
Again, following Day and Walter [3], we express these prevalence and incidence rates in terms 
of the false negative rate and of the sojourn time distribution. The following assumptions, which 
will often hold approximately, are made. 
(a) f(y)--probability density function of the sojourn time is independent of time t. 
(b) fl--the false negative rate is independent of both the lead time and the sojourn 
time. 
(c) J ( t )~the incidence of the preclinical state, i.e. the rate at which individuals enter 
it, is uniform for an individual over the duration of the study. 
With these assumptions, expressions are obtained for prevalence and incidence at various creens 
in terms of the three quantities listed in (a), (b) and (c) above. 
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For estimation of the parameters involved, the following assumptions are made: 
(i) The cases detected at screen i have a Poisson distribution. 
(ii) The cases emerging outside screening between screens i and i + 1 also have a 
Poisson distribution. 
Estimation of the distribution f (y)  and of the false negative rate fl can now proceed by maximum 
likelihood (ML) or minimum chi-square, provided that the function f is parameterized in some way. 
An exponential distribution is found to be not only computationally tractable but also provided 
a satisfactory fit to the data (based on chi-square goodness of fit test). 
Assumptions for the adjustment of the screening biases 
(1) Sojourn times are exponentially distributed. Therefore lead times are also 
exponentially distributed. 
(2) Survival times and randomly generated sojourn times are matched in agreement 
with a range of positive association. Adjustments are made for three choices of 
correlations, namely, 0.30 (low), 0.50) (med) and 1.0 (high). 
(3) Cytologic type of tumor and the age of the patients are assumed to be major 
confounding variables. For the former, lead time estimation and adjustment are 
done separately for each cytologic type. As for the later, Cox's regression analysis 
is performed. 
Justification of these assumptions can only be obtained indirectly since no randomized control 
group (unscreened group) exists. Model assumptions appear satisfactory as reflected in the 
goodness of fit statistics. The results of this analysis, both in terms of the distribution of the lead 
times as well as the survival benefits for the screen-detected cases are in the expected irection and 
magnitude. 
2. MATERIALS AND METHOD 
The details of the ELC study design and cohort characteristics have been given elsewhere [2]. 
Briefly, some 10,000 men, 45 years old or older, who smoked at least one pack of cigarettes per 
day, were enrolled at each of the institutions (Mayo Clinic, Johns Hopkins and Memorial 
Sloan-Kettering). They were offered screening for lung cancer for at least five years. Although there 
were several different screening modalities; for the purpose of this paper, we will consider only the 
approx. 10,000 men screened by "annual X-ray only" (about half each from Johns Hopkins 
and Memorial Sloan-Kettering). In this group, there were 291 lung cancer cases diagnosed uring 
the first six periodic yearly screenings. Of these 173 were detected by screening (X-ray) while 
still asymptomatic (screen-detected). The rest were detected between regular screenings (e.g. by 
accidental X-ray or by symptoms), and would be termed as clinically-detected cases. 
As mentioned earlier, our approach for this analysis requires that any relevant screening biases 
must be removed prior to estimating any benefits of screening and subsequent treatment. In this 
paper we focus on two of the major biases, namely, lead time and length sampling (for definitions, 
see Habbema et al. [1]). Patient self selection bias could not be identified and corrected here, since 
no randomized control group (without X-ray screening) exists. The other screening bias of over 
diagnosis is not considered in this paper. 
2.1. Estimation of lead time bias 
Before any adjustment for lead time bias can be made, good estimates of this bias are needed. 
Many investigators have studied the problem of estimating lead time [5-8, 10-12]. All of these have 
used the HIP study on breast cancer screening data. We believe it is useful to apply these stimation 
techniques to the lung cancer data and this is the subject of our future investigation. However, for 
the purpose of the present paper, the approach of Day and Walter [3, 13] has been used to estimate 
the mean lead time. Their approach does not require a randomized control group and hence is well 
suited for the current problem. 
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Briefly, in their approach, one needs the following data: 
(1) At each screen i, S,.---the number of screen-detected cases and N;---the number 
of persons creened. 
(2) Between screens i and i + 1, C,--the number of cases diagnosed (i.e. clinically- 
detected) and Y,--the number of person-years at risk. 
(3) For cases found after a given screening, the interval after the screening in which 
diagnosis is made. 
S~ and Cg are assumed to follow the Poisson distribution with parameters N~Pg and YiQi, 
respectively, where Pg is the total prevalence rate of the disease at screen i and Qi is the incidence 
rate of the cases between screen i and i + 1. Rates Pe and Q~ are modeled as functions of 
(a) the incidence of preclinical disease (J); 
(b) the false negative rate of the screening modality (fl); 
and 
(c) the distribution of lead times (for our data, the exponential distribution with 
parameter 2 was used). 
With this set up, the parameters can be estimated via the maximum likelihood or the minimum 
chi-square method. We use the latter. 
2.2. Adjustment of the lead time bias 
The actual lead time gained by each screen-detected case is, practically, unobservable. Let us 
assume, early detection of a case by screening, followed by treatment, is of no benefit, so far as 
increased survival is concerned. Lead time bias will simply result in a longer survival time (measured 
from the date of diagnosis) for a screen-detected case vis-g~-vis that of a clinically-diagnosed (but 
otherwise comparable to screen-detected) case. The "excess" survival being simply the lead time 
gained. Each screen-detected case presumably has some lead time gained. Adjustment of this bias 
from the survival times, on an individual basis, is difficult. The connection between these two 
intervals (i.e. lead time and survival time) rests on two associations, the association between lead 
time and duration of preclinical disease (sometimes referred to as sojourn time) and the possible 
association between duration of preclinical disease and survival after diagnosis. For any given 
duration of preclinical disease, D, lead times vary uniformly between 0 and D. Therefore long 
duration cases have a long range of possible lead times, but they do not routinely have long lead 
times. If there is little heterogeneity of durations within cytologic strata (i.e. within each cell-type 
of tumor), the lead times must correspondingly have little association with duration of preclinical 
disease. In the extreme, if strata are perfectly homogeneous, there is no variation of preclinical 
duration and therefore no association between duration and lead time. Even if one assumes that 
some variation exists within strata and therefore a weak association might exist between duration 
and lead time, it is the possible association between duration and the survival which should effect 
potential adjustments for such a bias from the survival of screen-detected cases. 
In the present paper, sojourn times are assumed to follow exponential distribution with some 
parameter 2. It follows, from the lack of memory property of an exponential distribution, that 
corresponding lead times also have an exponential distribution with same parameter 2. Conse- 
quently, a random sample of lead times generated from an exponential (2) is equivalent to a 
random sample of sojourn times from the same distribution. 
It is not clear from the literature as to the sign and magnitude of correlation between sojourn 
times and the survival times for lung cancer. Nevertheless, it would seem intuitively, that some 
positive correlation may exist between the two. Habbema et al. [1] assumed a positive correlation 
of specified magnitude for breast cancer, but gave no evidence for the assumption. The association 
seems to have been used only for illustrative purposes. There seems to be several approaches one 
can take in adjusting the survival for sojourn time and/or lead time biases: 
(1) assuming no association and displacing the survival curve, a constant interval, 
equal to mean lead time (or equivalently mean sojourn time, in the present paper); 
or  
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or  
(2) assuming an exponential distribution of sojourn time, generate a random sample 
of lead times and then matching randomly to the observed survival times of the 
clinical cases; 
(3) assuming an exponential distribution of sojourn and matching with survival 
times in agreement with some assumed weak positive association. Several assump- 
tions as to the strength of the association could be applied to determine the effect 
of the assumed correlation on the estimated hazard ratio in the comparison of 
screen-detected cases and clinically-detected cases. 
In the present paper approach (3) was taken. Adjustments were made for three choices of 
correlations, namely 0.30 (low) and 0.50 (rood) and 1.0 (high). 
2.3. Adjustment for cytologic type of tumor and age of patients 
Since squamous and adenocarcinoma cell types are believed to be slower growing lung cancer 
[14], one would expect more cases of these cell types among the screen-detected group, while the 
faster growing (oat/small cell types) lung cancers are likely to miss detection by screening and will 
more frequently develop between screens. Our approach to minimizing the potential confounding 
effect of the tumor cell-type on subsequent survival comparisons between screen-detected cases and 
clinically-detected cases, is to obtain the lead time estimates for different lung cancer cell types and 
then adjust the survival experiences of clinically-detected cases within each lung cancer cell type. 
Further, survival comparisons are done separately for each cell type. In particular, we stratify the 
data into three categories, i.e. squamous, adenocarcinoma/large and oat/small. Then we proceed 
to estimate and adjust for lead time separately for each category. Since a broad characterization 
of tumor growth is by cell type, this stratification would minimize much of the confounding 
potential of cytologic type on survival. As indicated in the next section, adjustments for age 
differences ( creen-detected vs clinically-detected) while estimating survival benefits, adjusts for any 
potential confounding effect of patient's age on survival. Patients with slow-growing cancers are 
generally older than those with rapidly growing ones [15]. So removing the effect of age differences 
on the survival was also reducing any bias in survival comparisons of screen-detected cases vs those 
who were not detected by the screening. 
2.4. Assessment of screening benefits 
Following the adjustments of the screening biases, the adjusted overall survival curve is 
compared with the survival curve of the screen-detected cases. Note that the groups whose 
survivals are to be compared (i.e. screen-detected vs clinically-detected) are not randomized 
groups. There is a possibility of covariate-confounding, i.e. the two groups may differ signifi- 
cantly with respect o some of the covariates (such as age of the patients) which are known 
or suspected to affect survival of cancer patients after diagnosis. Therefore, Cox regression 
analyses are performed to account for some of the covariate heterogeneity between groups. 
The survival is measured from the date of diagnosis until death. All those survival times are 
considered censored for which death is due to other causes (other than lung cancer) or for which 
the patient was still alive at the end of the study or was lost to follow up. There was no case 
lost to follow up. 
3. RESULTS AND DISCUSSION 
Table 1 contains summary information on lung cancer cases found within 6 y of screening. 
In this table and in the analyses, only "regular" attenders are included. The definition of a regular 
attender is same as used by Day and Walter, i.e.; a person who did not miss any intermediate screen 
prior to his last screen was considered regular. In the present setup of lead time estimation, it is 
important to consider only the regular attenders, ince the effect of missing a screen confounds the 
true effect of screening. Thus a person who had one negative screen and missed all later screens 
would be included. If, however, he attended the initial screen and the third follow-up, but missed 
follow-ups 1 and 2, he would be excluded. 
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Table 1. Lung cancer prevalence and incidence by cell type 
Cases 
Squamous Adenocarcinoma/large Oat/small Other Total 
I I  43 9 0 63 
6 23 5 0 34 
5 11 0 0 16 
9 12 3 l 25 
3 15 l 2 21 
5 9 0 0 14 
Previously Person Cases 
negative years 
screen at risk Squamous Adenocarcinoma/large Oat/small Total 
10031 2 3 5 10 
1757 0 3 2 5 
883 1 1 0 2 
748 3 2 1 6 
678 I 4 1 6 
575 0 4 0 4 
430 l 2 1 4 
8010 4 5 6 15 
1570 l 4 0 5 
699 l l l 3 
539 l 0 0 1 
430 1 l 0 2 
313 0 2 0 2 
6670 2 2 3 7 
1289 1 1 2 4 
530 0 0 l l 
358 1 1 0 2 
264 1 0 0 l 
5627 2 6 3 I I  
1096 2 1 1 4 
412 0 l 2 3 
267 0 I 0 l 
4730 5 1 I 7 
699 0 2 0 2 
226 0 l 0 1 
3831 3 1 2 6 
774 0 2 I 3 
An exponential distribution for the lead times was found to adequately fit our data (see the 
chi-square "goodness of fit" values in Tables 2 and 3). Unlike the HIP breast cancer data, there 
is no independent estimate of the incidence rate J of the preclinical disease, since there is no 
randomized group that was not screened. Therefore, initially all three parameters (J, fl and 2) were 
estimated. Simultaneous estimation of the parameters resulted in a value of 0 for fl for each cell 
type except oat/small. Although, biologically implausible, it does suggest hat the value of fl (as 
defined in their paper by Walter and Day) is in fact a small number. We set the value of fl equal 
to 0.05 and reestimated the other two parameters (J  and 2) for each cell type. Tables 2 and 3 
give the values of the estimated parameters (including the mean lead time for each of the three 
Table 2. Simultaneous estimates for all three parameters 
Squamous Adenocarcinoma/large Oat/small Total 
J-Incidence of preelinical disease 0.0015 0.0030 0.0010 0.0051 
J-False negative 0.00 0.00 0.41 0.00 
Mean lead time 0.906 1.590 1.236 1.272 
Chi-squar¢ 23.9 27.8 21.9 18.1 
d.f. 30 30 30 30 
Table 3. Estimates when B is 0.05 
Squan'lous 
J-Incidence of preclinical disease 0.0615 
Mean lead time 0.958 
Chi-square 24. I 
d.f. 31 
Adenocarcinoma/large Oat/small Total 
0.0029 0.0010 0.0051 
1.695 0.709 1.351 
28.7 22.3 18.7 
31 31 31 
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cell types). The estimated mean lead time was not very sensitive to the changes in the value of/~. 
Note that the mean lead time for adeno/large c lls is largest (1.70 y), followed by squamous (0.95 y), 
and then oat/small cells (0.71 y). 
The results of the lead time estimation analysis are in the expected irection. Chest X-ray is 
known to be best in picking up peripheral tumors, which tend to be adenocarcinoma. Squamous 
cell carcinoma is not so easily picked up by chest X-ray. Small cell carcinoma grows so fast that 
frequently an annual interval for X-ray screening is too large for picking up asymptomatic small 
cell lung cancer. 
Following the lead time adjustments (outlined in the previous ection), survival curves were 
obtained for screen-detected (S),adjusted clinically-detected (A), and clinically-detected cases (C). 
Figures 1-3 contain these curves for squamous, adenocarcinoma/large andoat/small cell types, 
respectively. Figure 4 contains these curves for all the cell types combined where the lead time 
adjustments are done by each cell type. Similar general results were obtained when a range of 
correlations (between sojourn time and survival) were assumed. Figures 5 and 6 give the survival 
curves for 0.30 and 0.50 correlations, respectively. 
Cox regression analyses were performed for each situation of adjustment, namely, no correlation, 
low, medium and high correlations between sojourn times and survival times. The conclusions 
obtained from these analyses were similar. We give here only the results for high correlation 
adjustments. Table 4 contains the results of the Cox regression analysis using the adjusted survival 
times for the clinically-detected cases. SCREEN was a dummy variable coded 1 if screen-detected 
and 0 if clinically detected. The variable AGE is the subjects' age at entry in years. There were 
significant survival differences between screen- and clinically-detected cases for all cell types prior 
to lead time adjustments. After bias adjustments, however, statistically significant differences 
persisted only in the analyses of the combined ata (P -- 0.001) and for adenocarcinoma/large cell 
cancer (P ~- 0.03). Again similar results were obtained for various ranges of assumed correlations 
between sojourn time and survival. 
These findings of significant survival benefit can be interpreted tosuggest that annual chest X-ray 
screening of high risk men is beneficial, particularly for those with lung cancer of adenocarcinoma 
and large cell types. It is possible that the relatively small number of squamous cell cases diagnosed 
by X-ray alone may be a reason that statistically significant prolongation of survival were not 
attained in our data. Nevertheless, difference as to 5 y case survival rates between screen-detected 
and adjusted clinically-detected cases is certainly large. Specifically, for adenocarcinoma/large cells, 
approx. 18% more survived in the screen-detected group, which translates to about 22 lives saved 
for 5 y beyond lung cancer diagnosis. 
As for squamous cell cancers, 5y survival rate was 16% better for screen-detected cases (over 
the adjusted survival rate for clinically-detected cases). Over all cell-types combined, improvement 
in 5 y survival was about 20%, giving a saving of about 40 lives at the end of a 5 y period with 
lung cancer. 
The results of this analysis uggest that: 
(l) Although a randomized control group is unavailable for any appropriate 
mortality comparisons, yet some insight can be derived as to the benefits of 
periodic screening by chest X-ray. 
(2) After accounting for major screening biases, there is significantly onger survival 
for screen-detected cases than for cases not detected by screening. 
(3) Using the logic of Habbema et al. [1], if a randomized clinical trial was done to 
evaluate X-ray screening, the actual mortality reductions due to screening could 
indeed be much larger than suggested in this analysis. 
The ELC detection study was designed in the early 1970s primarily to investigate sputum 
cytology as an adjunct to radiology for early detection of lung cancer. It was not believed that 
periodic screening by X-ray alone might turn out to be useful. Consequently, there was no 
randomized control group in the study which can be used to assess mortality reduction "by X-ray 
screening alone." 
The type of analysis done in this paper is one way to estimate benefits of chest X-ray screening 
in early diagnosis of lung cancer. The findings here are consistent with the beliefs of ELC study 
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Fig. i. Squamous cell type survival curves adjusted by mean lead time of 0.958 y. Fig. 2. Adenocarcinoma/large cell type survival curves adjusted by mean lead time of 1.695 y. 
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Table 4. Itwults of the Cox rqpms/on analysis 
Squamoue Cod'. grD Error P.Value 
Semen -0.790 0.312 0,011 Unadjusted for lead time Age 0.031 0.022 0.149 
Screen -0,445 0.300 0.139 Adjusted for lead time Age 0,032 0.022 0.135 
Adenocarclnoma /large 
Screen - 1.001 0.200 0.000 Unadjusted for lead time Age 0.030 0.013 0.016 
Screen - 0.429 0.198 0.030 Adjusted for lead time Age 0.029 0.0 !3 0.024 
Oat~small 
Screen -0.992 0.336 0.003 
Unadjusted for lead time Age 0.010 0.020 0.615 
Screen -0.155 0.31 0.619 Adjusted for lead time Age 0.016 0.021 0.447 
All separately by cell type 
Screen -0.993 0,143 0.000 Unadjusted for lead time Age 0.025 0.010 0.001 
Screen -0.510 0.139 0.001 Adjusted for lead time Age 0.024 0.010 0.010 
investigators [16-18], and the results of a recent randomized study [19], although the prior literature 
on the value of X-ray screening for lung cancer [9] was not positive. 
It is worthwhile to point out here that the statistical evidence of the benefit of X-ray screening 
as given in this paper is based on the following assumptions: 
(a) The statistical model assumed to estimate lead time distribution is valid 
and 
(b) the relevant screening biases are in fact removed. 
Unlike the classic HIP data on breast cancer screening, we do not have the "control" group 
(nonscreened) or the data for the "refusers". In that sense, a direct validation of our results on 
the basis of relevant mortality analysis, where the biases would be absent, cannot be obtained. 
However, if the interpretation of the results of Habbema et al. [1] could be applied to our data, 
then it would follow that the estimated benefits would only increase, had there been a control 
group. 
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